標(biāo)題: Titlebook: Clinical Management of Renal Tumors; Ronald M. Bukowski,Andrew C. Novick Book 2008 The Editor(s) (if applicable) and The Author(s), under [打印本頁(yè)] 作者: POL 時(shí)間: 2025-3-21 19:53
書(shū)目名稱Clinical Management of Renal Tumors影響因子(影響力)
書(shū)目名稱Clinical Management of Renal Tumors影響因子(影響力)學(xué)科排名
書(shū)目名稱Clinical Management of Renal Tumors網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱Clinical Management of Renal Tumors網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱Clinical Management of Renal Tumors被引頻次
書(shū)目名稱Clinical Management of Renal Tumors被引頻次學(xué)科排名
書(shū)目名稱Clinical Management of Renal Tumors年度引用
書(shū)目名稱Clinical Management of Renal Tumors年度引用學(xué)科排名
書(shū)目名稱Clinical Management of Renal Tumors讀者反饋
書(shū)目名稱Clinical Management of Renal Tumors讀者反饋學(xué)科排名
作者: BLANC 時(shí)間: 2025-3-21 22:06 作者: 抵押貸款 時(shí)間: 2025-3-22 01:00
Deutschen Gesellschaft für Neurochirurgierecent identification of novel clinical and pathologic prognostic factors in RCC have resulted in gradual transition from the use of solitary clinical factors, such as tumor, node, metastasis staging system, to the introduction of systems that integrate multiple validated prognostic factors. Finally作者: 管理員 時(shí)間: 2025-3-22 08:23
Probleme der Sch?deldachplastikors, used varying definitions, and/or treated different patient populations, and therefore, it is difficult to fully assess their value as independent prognostic indicators..In addition to these “classical” predictors, new molecular based technologies are helping to better define the biology of rena作者: MERIT 時(shí)間: 2025-3-22 12:23
T-cell Unresponsiveness in Renal Cell Carcinoma Patients, Muc-1, and Her-2/neu, but also several that may be unique to RCC..–. Despite the potential for an effective immune response to RCC, it is not well developed in this patient population even after implement of various forms of immunotherapy designed to stimulate tumor immunity. The presence of an ine作者: Visual-Field 時(shí)間: 2025-3-22 15:37 作者: Visual-Field 時(shí)間: 2025-3-22 20:54
Surveillance Strategies Following Curative Therapy for Localized Renal Cell Carcinoma,recent identification of novel clinical and pathologic prognostic factors in RCC have resulted in gradual transition from the use of solitary clinical factors, such as tumor, node, metastasis staging system, to the introduction of systems that integrate multiple validated prognostic factors. Finally作者: 檢查 時(shí)間: 2025-3-22 22:59 作者: inhumane 時(shí)間: 2025-3-23 04:14 作者: 財(cái)政 時(shí)間: 2025-3-23 08:33
The Role of Percutaneous Imaging-Guided Biopsy in the Diagnosis and Management of Renal Masses,ary renal neoplasms from renal tumors not treated surgically, such as metastatic disease and lymphoma. Percutaneous biopsy is also used to differentiate primary neoplasms from benign renal lesions and to establish a diagnosis of renal cell carcinoma in those patients with widespread metastatic disease or with contraindications to surgery.作者: Conquest 時(shí)間: 2025-3-23 13:47
Radical Nephrectomy,, and a lymph node dissection, removing the paraaortic and paracaval nodal packets from the crus of the diaphragm superiorly to the aortic bifurcation inferiorly. Since that time, the technique of radical nephrectomy has undergone some modification, but the general principles outlined remain germane to today’s contemporary practice.作者: 輕而薄 時(shí)間: 2025-3-23 14:12 作者: 全能 時(shí)間: 2025-3-23 20:13 作者: 細(xì)胞膜 時(shí)間: 2025-3-24 01:59
th renal cancer having localized or advanced disease are discussed. Surgical approaches for primary and metastatic tumors, symptom palliation, and systemic therapy for metastatic disease including immunotherapy and targeted approaches are discussed in detail..978-1-60761-469-2978-1-60327-149-3作者: JEER 時(shí)間: 2025-3-24 05:41
https://doi.org/10.1007/978-3-642-88120-6s and experimental studies. Furthermore, pathologists could allocate any redundant tumor tissues not required for diagnosis to basic research programs. Pathologists, urologists, and other clinicians play equally important roles in the optimal handling and processing of renal cell carcinoma specimens.作者: 打擊 時(shí)間: 2025-3-24 09:32 作者: 經(jīng)典 時(shí)間: 2025-3-24 14:14
Probleme der Sch?deldachplastikradiologic data will be of importance to validate results if a surrogate endpoint such as disease free survival is utilized. In view of our current knowledge of the biology of clear cell carcinoma, studies utiling medications such as sunitinib, sorafenib, or bevacizumab are considerations.作者: Apogee 時(shí)間: 2025-3-24 18:17 作者: 偽書(shū) 時(shí)間: 2025-3-24 20:11 作者: 遺留之物 時(shí)間: 2025-3-25 01:57
Adjuvant Therapy of Renal Cell Carcinoma,radiologic data will be of importance to validate results if a surrogate endpoint such as disease free survival is utilized. In view of our current knowledge of the biology of clear cell carcinoma, studies utiling medications such as sunitinib, sorafenib, or bevacizumab are considerations.作者: expound 時(shí)間: 2025-3-25 05:20
rage.Details both medical and surgical approaches to therapy.Clinical Management of Renal Tumors.?provides an in-depth review of the data relating to the management of renal tumors as well as an updated description regarding pathologic and molecular classification of renal tumors. The neoplasms cove作者: DUST 時(shí)間: 2025-3-25 09:30
https://doi.org/10.1007/978-3-642-88120-6 surgical and nonsurgical disease. Computed tomography (CT) and magnetic resonance (MR) exams of renal cell carcinoma should be designed to maximize identification of prognostic factors as well as staging features: size, extension outside the renal capsule and fascia, lymphadenopathy, renal vein invasion, and metastatic disease.作者: 取回 時(shí)間: 2025-3-25 13:28 作者: Indecisive 時(shí)間: 2025-3-25 18:12 作者: Embolic-Stroke 時(shí)間: 2025-3-25 20:21
R?ntgendiagnostik im Kindesaltertically improved. Unfortunately, the same cannot be said for advanced kidney cancer, which remains incurable despite medical progress. This chapter reviews the signs, symptoms, common clinical presentations of patients with renal cancer, and discusses the current approaches to establishing a diagnosis of renal cancer.作者: BRIEF 時(shí)間: 2025-3-26 01:17 作者: Arteriography 時(shí)間: 2025-3-26 04:29 作者: 緯線 時(shí)間: 2025-3-26 10:34 作者: 合群 時(shí)間: 2025-3-26 14:33 作者: Trochlea 時(shí)間: 2025-3-26 17:11 作者: 淘氣 時(shí)間: 2025-3-26 21:34 作者: VICT 時(shí)間: 2025-3-27 02:13 作者: 高歌 時(shí)間: 2025-3-27 08:08 作者: Silent-Ischemia 時(shí)間: 2025-3-27 12:02 作者: Genistein 時(shí)間: 2025-3-27 15:05 作者: Gudgeon 時(shí)間: 2025-3-27 21:07 作者: Extort 時(shí)間: 2025-3-27 23:57 作者: 彩色的蠟筆 時(shí)間: 2025-3-28 04:32
Book 2008tion regarding pathologic and molecular classification of renal tumors. The neoplasms covered include clear cell carcinomas, papillary cancers, nonepithelial tumors, and other mass lesions that resemble tumors. The management of patients with renal cancer having localized or advanced disease are dis作者: 螢火蟲(chóng) 時(shí)間: 2025-3-28 08:00
Renal Cell Carcinoma: ,,iagnosed in patients ranging from 40 to 70 years of age, with a male predominance of 1.6 to 1.0.. A comparison of 43,685 cases of renal cancer diagnosed in the period 1973 to 1985 with those diagnosed from 1986 to 1998 (Surveillance, Epidemiology, and End Results [SEER] database) demonstrated a marg作者: Aqueous-Humor 時(shí)間: 2025-3-28 14:24 作者: 絆住 時(shí)間: 2025-3-28 17:25
The Role of Percutaneous Imaging-Guided Biopsy in the Diagnosis and Management of Renal Masses,ing-guided biopsy of renal masses is a safe, accurate, and lower-cost alternative to surgical biopsy. It can be performed in an outpatient setting and is frequently all that is necessary to establish a diagnosis and effect patient management. Percutaneous biopsy is largely used to differentiate prim作者: Crater 時(shí)間: 2025-3-28 21:31 作者: PALSY 時(shí)間: 2025-3-29 00:00 作者: GREEN 時(shí)間: 2025-3-29 05:21 作者: cogent 時(shí)間: 2025-3-29 10:17
T-cell Unresponsiveness in Renal Cell Carcinoma Patients,e infrequent though detectable occurrences of spontaneous regression in renal cell carcinoma (RCC) patients. and by the higher incidence of renal cell tumors in patients that are immuno-suppressed after receiving kidney allografts..–. There is also a significant infiltrate of T lymphocytes in many p作者: conformity 時(shí)間: 2025-3-29 14:26
Renal Cell Carcinoma: ,,of environmental factors. Due to advances in radiographic imaging modalities and surgical techniques, cure rates for low-stage renal cancer have dramatically improved. Unfortunately, the same cannot be said for advanced kidney cancer, which remains incurable despite medical progress. This chapter re作者: 入會(huì) 時(shí)間: 2025-3-29 19:23 作者: CLEAR 時(shí)間: 2025-3-29 20:18
Active Surveillance of Localized Renal Tumors,l body imaging. Active surveillance of these lesions has been pursued in elderly or infirm patients. Here we review the current data regarding the growth kinetics, pathology, stage progression, and clinical management of renal masses under active surveillance. The limitations of these data are discu作者: Bereavement 時(shí)間: 2025-3-30 01:12
Radical Nephrectomy, was described by Robson et al.. The technique of radical nephrectomy can be performed in a variety of ways, but the firm principles outlined by Robson remain relevant today. Robson and associates described removing the kidney with early ligation of the renal artery and vein to minimize tumor emboli作者: 領(lǐng)導(dǎo)權(quán) 時(shí)間: 2025-3-30 05:22 作者: HERE 時(shí)間: 2025-3-30 11:57 作者: BURSA 時(shí)間: 2025-3-30 15:03 作者: Limerick 時(shí)間: 2025-3-30 16:47
The Role of Angioinfarction in the Management of Renal Tumors,ogenesis pathways by eliminating the tumor’s blood supply. Angioinfarction of renal tumors may be used to both the surgeon’s and patient’s advantage. Here we review the history, indications, techniques, and complications of angioinfarction in the management of primary renal tumors and their metastas作者: Insensate 時(shí)間: 2025-3-30 23:24
Surveillance Strategies Following Curative Therapy for Localized Renal Cell Carcinoma,lly recurrent and metastatic disease. Assuming that success of clinical intervention at the time of relapse is inversely proportional to the disease burden at the time of salvage treatment, ideal surveillance protocol should allow the earliest identification of potentially treatable recurrences whil作者: Aids209 時(shí)間: 2025-3-31 01:18
Local Recurrence of Renal Cell Carcinoma: ,,l encapsulated. Local recurrence presents unique challenges. This chapter reviews the incidence, risk factors, and management of local recurrence for patients with RCC. Local recurrence occurs primarily as ipsilateral recurrence in the renal fossa after radical nephrectomy and within the residual pa作者: N防腐劑 時(shí)間: 2025-3-31 05:14
Adjuvant Therapy of Renal Cell Carcinoma,ed studies available do not demonstrate an advantage for pre- or postoperative therapy. Patient selection criteria have varied, but generally high risk groups with T. tumors and lymph node metastases (N.) disease have been included. In the future, adjuvant trials conducted in this group of patients 作者: GLUT 時(shí)間: 2025-3-31 12:04 作者: CHAR 時(shí)間: 2025-3-31 16:56
Active Surveillance of Localized Renal Tumors,l body imaging. Active surveillance of these lesions has been pursued in elderly or infirm patients. Here we review the current data regarding the growth kinetics, pathology, stage progression, and clinical management of renal masses under active surveillance. The limitations of these data are discussed.作者: enumaerate 時(shí)間: 2025-3-31 20:04
The Role of Angioinfarction in the Management of Renal Tumors,ogenesis pathways by eliminating the tumor’s blood supply. Angioinfarction of renal tumors may be used to both the surgeon’s and patient’s advantage. Here we review the history, indications, techniques, and complications of angioinfarction in the management of primary renal tumors and their metastases.作者: 愛(ài)管閑事 時(shí)間: 2025-3-31 22:13 作者: 男學(xué)院 時(shí)間: 2025-4-1 04:43
https://doi.org/10.1007/978-3-642-88120-6imary renal neoplasms, and provide surgical planning information. Imaging is also used to distinguish between benign and malignant disease and between surgical and nonsurgical disease. Computed tomography (CT) and magnetic resonance (MR) exams of renal cell carcinoma should be designed to maximize i作者: 加強(qiáng)防衛(wèi) 時(shí)間: 2025-4-1 06:37 作者: amorphous 時(shí)間: 2025-4-1 12:44
https://doi.org/10.1007/978-3-642-88120-6present over 90% of all the tumors in adult kidneys. These tumors have characteristic pathologic, cytogenetic, and molecular characteristics, and biologic behavior and therapeutic outcomes. The 2004 World Health Organization classification of renal tumors represent the most updated classification sy
